The clinical development and introduction into practice of checkpoint inhibitors that reinvigorate the immune system to target tumors have revolutionized the treatment paradigm for patients with lung cancer.
- 2010: MD, PhD, State University of New York Upstate Medical University, Syracuce
- 2010 - 2011: Intern, internal medicine, Barnes-Jewish Hospital, St. Louis
- 2011 - 2012: Resident, internal medicine, Barnes-Jewish Hospital
- 2012 - 2016: Fellow, hematology/oncology, Washington University, St. Louis
Disclaimer: This listing may not include all articles associated with this physician and may include publications related to other physicians with a similar name.